Firmagon receives EU recommendation for prostate cancer
This article was originally published in Scrip
Executive Summary
Ferring Pharmaceuticals' novel prostate cancer drug Firmagon (degarelix) has been granted a recommendation for marketing approval from the EU's CHMPfor the treatment of patients with advanced hormone-dependent prostate cancer. Ferring plans to launch the drug in Europe in the first quarter of 2009 and is also awaiting an imminent decision from the US FDA on approval of the drug.